Monday, August 21, 2017
Molecular Health, a pioneer in data and analytics-driven precision medicine from Heidelberg, Germany, seeks to expand its efforts to establish collaborations in Asia and the precision-medicine scene there.
In cooperation with its strategic partners, which include some of the world’s best laboratories, universities, and genetic facilities, Molecular Health plans to bring its technology (Dataome ® ) to a region of the world that has started to take considerable steps towards genome sequencing and custom-tailored cancer treatments for individual patients. The ultimate goal is improving patient care.
“Strategic partnerships are a critical component of the design of our company, and our market partners enable us to efficiently bring our products to market,” says Friedrich von Bohlen und Halbach, Chief Executive Officer, speaking of Molecular Health Guide ® (MH Guide). This is a treatment decision-support tool in oncology for physicians, hospitals and diagnostic laboratories and is one of the company’s major products.
The MH Guide software is registered as an in-vitro diagnostic medical device (IVD) in Europe and is CE-compliant with European regulations. MH Guide includes all of the steps of the clinical genomics workflow in oncology, from raw sequencing data to generating an interactive, editable medical report. It is the first product of its kind in Germany to be reimbursed by public health insurance.
In the future, targeted approaches in oncological therapy will play an important role in treating patients. As tumors are genetically characterized, patient groups most likely to benefit from targeted therapy approaches can be identified prior to treatment.
To learn more about Molecular Health or experience an MH Guide demo, visit us at our booth in the Grand Hilton hotel, exhibition floor, space no. 2.
MEDIA CONTACT
Dr. Xiaoyue Wang
xiaoyue.wang@molecularhealth.com
(++49) 6221 43851-2280
ABOUT MOLECULAR HEALTH
Molecular Health is a precision medicine company which applies data and analytics via medical devices to help cancer patients and physicians find personalized diagnostic strategies. Molecular Health has its headquarters in Heidelberg, Germany, and a subsidiary located in Boston.
The company provides a fast and scalable platform (Dataome ® ) that turns the latest biomedical information into clinically actionable knowledge to improve individual patient outcomes.
Molecular Health was founded in 2004, and since then it has stood for transforming big data into precise, actionable decisions for all stakeholders in healthcare.
Its range of products is used across the healthcare sector. As more precise ways of practicing medicine have an effect on treating patients and developing effective drugs, data interpretation is growing increasingly complex. Molecular Health is CE-compliant with European regulations on medical devices.
The company is financed by Dievini Hopp BioTech, an investment vehicle of former SAP CEO and founder Dietmar Hopp.
